Back to top
more

OPKO Health (OPK)

(Delayed Data from NSDQ)

$1.19 USD

1.19
7,424,202

-0.09 (-7.03%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $1.18 -0.01 (-0.84%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands

by Zacks Equity Research

OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.

Zacks Equity Research

Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of -58.33% and -5.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

by Zacks Equity Research

OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.

Zacks Equity Research

OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands

by Zacks Equity Research

Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.

Zacks Equity Research

OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for OPKO Health (OPK) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of -66.67% and 8.87%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround

by Zacks Equity Research

OPKO Health (OPK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

by Zacks Equity Research

OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.

Zacks Equity Research

Labcorp is Set to Acquire Select Assets of BioReference Health of OPK

by Zacks Equity Research

LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.

Zacks Equity Research

OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands

by Zacks Equity Research

The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.

Zacks Equity Research

OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 109.09% and 18.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 0% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Countdown to OPKO Health (OPK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of OPKO Health (OPK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

by Zacks Equity Research

OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.

Zacks Equity Research

OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains

by Zacks Equity Research

OPK aims to advance a novel vaccine candidate for EBV infection, provide protective immunity to patients and prevent these diseases.

Zacks Equity Research

OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.

Zacks Equity Research

Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings

by Zacks Equity Research

Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

OPKO Health (OPK) Q3 Earnings Surpass Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 130% and 4.26%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Waters (WAT) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Waters (WAT) delivered earnings and revenue surprises of 9.33% and 3.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies

by Zacks Equity Research

OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.

Zacks Equity Research

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

by Zacks Equity Research

OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.

Zacks Equity Research

ENTX & OPK Stock May Gain Following Positive PK/PD Research Data

by Zacks Equity Research

Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.

Zacks Equity Research

OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.